Methoxphenidine (MXP, 2-MeO-Diphenidine) is a dissociative drug that has been sold online as a research chemical. 2-MeO-diphenidine was first reported in a 1989 patent where it was tested as a treatment for neurotoxic injury, though it possesses a lower affinity for the NMDA receptor than the related compound diphenidine, anecdotal reports suggest 2-MeO-diphenidine has greater oral potency. Of the three isomeric anisyl-substituents 2-MeO-diphenidine has affinity for the NMDA receptor that is higher than 4-MeO-diphenidine but lower than 3-MeO-diphenidine, a structureâ€"activity relationship shared by the arylcyclohexylamines.
Acute methoxphenidine intoxication has been reported to produce confusion, hypertension, and tachycardia that was responsive to treatment with intravenous lorazepam, methoxphenidine has also been associated with three published fatalities.
§See also
- Diphenidine
- Lefetamine
- Methoxetamine
- MT-45
- NMDA receptor antagonist
- Phencyclidine
§References
